Systematic review of Marburg virus vaccine nonhuman primate studies and human clinical trials
| Autor: | Christine Lee, Jack N Hutter, Paige E. Waterman, Nicholas Dulin, Melinda J. Morton Hamer, Adam Spanier, Kristen Merino |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Primates
030231 tropical medicine medicine.disease_cause Virus DNA vaccination Marburg virus 03 medical and health sciences 0302 clinical medicine Immunity Animals Humans Medicine 030212 general & internal medicine Ebola virus General Veterinary General Immunology and Microbiology biology business.industry Immunogenicity Public Health Environmental and Occupational Health Viral Vaccines Hemorrhagic Fever Ebola Ebolavirus biology.organism_classification Virology Clinical trial Infectious Diseases Marburgvirus Vesicular stomatitis virus Molecular Medicine business |
| Zdroj: | Vaccine. 39:202-208 |
| ISSN: | 0264-410X |
| DOI: | 10.1016/j.vaccine.2020.11.042 |
| Popis: | Background Recent deadly outbreaks of Marburg virus underscore the need for an effective vaccine. A summary of the latest research is needed for this WHO priority pathogen. This systematic review aimed to determine progress towards a vaccine for Marburg virus. Methods Article search criteria were developed to query PubMed for peer-reviewed articles from 1990 through 2019 on Marburg virus vaccine clinical trials in humans and pre-clinical studies in non-human primates (NHP). Abstracts were reviewed by two authors. Relevant articles were reviewed in full. Discrepancies were resolved by a third author. Data abstracted included year, author, title, vaccine construct, number of subjects, efficacy, and demographics. Assessment for risk of bias was performed using the Syrcle tool for animal studies, and the Cochrane Collaboration risk of bias tool for human studies. Results 101 articles were identified; 27 were related to Marburg vaccines. After full text review, 21 articles were selected. 215 human subjects were in three phase 1 clinical trials, and 203 NHP in 18 studies. Vaccine constructs were DNA plasmids, recombinant vesicular stomatitis virus (VSV) vectors, adenovirus vectors, virus-like particles (VLP), among others. Two human phase 1 studies of DNA vaccines had 4 adverse effects requiring vaccine discontinuation among 128 participants and 31–80% immunogenicity. In NHP challenge studies, 100% survival was seen in 6 VSV vectored vaccines, 2 DNA vaccines, 2 VLP vaccines, and in 1 adenoviral vectored vaccine. Conclusion In human trials, two Marburg DNA vaccines provided either low immunogenicity or a failure to elicit durable immunity. A variety of NHP candidate Marburg vaccines demonstrated favorable survival and immunogenicity parameters, to include VSV, VLP, and adenoviral vectored vaccines. Elevated binding antibodies appeared to be consistently associated with protection across the NHP challenge studies. Further human trials are needed to advance vaccines to limit the spread of this highly lethal virus. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect